Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirty-one ratings firms that are currently covering the firm, Marketbeat reports. Nine research analysts have rated the stock with a hold recommendation, twenty-one